SPRAVATO® (esketamine) for Treatment-Resistant Depression: What Orange County Patients Should Know

When Depression Persists Despite Your Best Efforts

Depression is more than sadness. It can affect cognition, relationships, professional performance, physical energy, and a person’s sense of identity. Many individuals respond well to antidepressant medications and psychotherapy. However, a significant number of patients continue to struggle even after trying multiple treatment options.   For individuals in Orange County, particularly those seeking care in Newport Beach and San Juan Capistrano, persistent symptoms can feel discouraging. It is common to wonder whether relief is possible when standard treatments have not produced meaningful improvement. Fortunately, advances in neuroscience have expanded the range of available therapies.   SPRAVATO® (esketamine) for treatment-resistant depression in Orange County offers a carefully supervised, FDA-approved option for adults whose depression has not responded to at least two adequate antidepressant trials. At Resiliency Mind+Body Medicine, this therapy is delivered with clinical precision and individualized care.

Understanding SPRAVATO® (esketamine) and Its Unique Mechanism

SPRAVATO® (esketamine) is a prescription nasal spray containing esketamine, a derivative of ketamine. Unlike traditional antidepressants, which primarily influence serotonin, norepinephrine, or dopamine, SPRAVATO® (esketamine) acts on the brain’s glutamate system. Glutamate plays an essential role in neural communication, synaptic plasticity, and mood regulation.   Research suggests that by targeting glutamate pathways, esketamine may help restore connections between brain cells that have been impaired by chronic depression. This mechanism differs significantly from conventional medications, which may take weeks to months to produce noticeable effects.   SPRAVATO® (esketamine) is administered in a certified medical setting under supervision. At Resiliency Mind+Body Medicine in Newport Beach and San Juan Capistrano, patients self-administer the nasal spray while clinicians monitor vital signs and overall comfort. Each visit includes a structured observation period to ensure safety and support.   It is important to understand that SPRAVATO® (esketamine) is not a replacement for oral antidepressants. It is prescribed alongside an existing antidepressant as part of a comprehensive treatment plan.

Recognizing the Impact of Treatment-Resistant Depression

Treatment-resistant depression is typically defined as major depressive disorder that does not improve after trying at least two different antidepressants at appropriate doses and duration. This experience can be emotionally taxing. Patients often report cycles of hope followed by disappointment as each new medication fails to bring sufficient relief.   Symptoms may include persistent low mood, diminished interest in previously enjoyable activities, sleep disturbances, appetite changes, fatigue, slowed thinking, and feelings of worthlessness. Some individuals may also experience intrusive or suicidal thoughts. These symptoms can interfere with work performance, family relationships, and overall well-being.   In high-achieving communities such as Newport Beach and the surrounding Orange County areas, patients may feel pressure to continue functioning outwardly despite significant internal distress. This discrepancy between external expectations and internal experience can deepen feelings of isolation.   Treatment-resistant depression does not reflect personal weakness or a lack of effort. It reflects the complexity of brain chemistry and the individualized nature of psychiatric conditions. Expanding treatment options allows patients to pursue care that aligns with their unique neurobiology.

A Personalized Treatment Experience at Resiliency Mind+Body Medicine

At Resiliency Mind+Body Medicine, SPRAVATO® (esketamine) treatment begins with a comprehensive psychiatric evaluation. Providers carefully review past medication trials, current symptoms, medical history, and treatment goals. This thorough assessment ensures that SPRAVATO® (esketamine) is both clinically appropriate and safe.   The initial treatment phase typically involves twice-weekly sessions for several weeks. Each appointment takes place in a private, calming environment designed to promote comfort. After self-administering the nasal spray, patients remain in the office for approximately two hours while clinicians monitor blood pressure and overall response.   As patients begin to experience improvement, treatment frequency is gradually reduced. Maintenance schedules vary depending on individual response and long-term goals. Throughout the process, providers maintain close communication to assess progress and adjust the care plan accordingly.   SPRAVATO® (esketamine) is often integrated into a broader therapeutic strategy that may include psychotherapy, lifestyle support, and ongoing medication management. This holistic framework reflects the mind and body philosophy central to the practice.

What Patients Can Realistically Expect

During a SPRAVATO® (esketamine) session, some patients experience temporary dissociation, changes in perception, or mild dizziness. These effects are typically short-lived and resolve before leaving the office. Because of these potential sensations, patients must arrange transportation home after each treatment.   Improvements may begin to emerge within days or weeks, although individual response varies. Early changes may include improved mental clarity, increased motivation, or reduced emotional heaviness. Over time, these shifts can translate into enhanced daily functioning and renewed engagement with meaningful activities.   It is important to approach treatment with realistic expectations. SPRAVATO® (esketamine) is not an instant cure, and outcomes vary among individuals. Some patients achieve significant symptom reduction, while others experience more moderate improvement that enhances quality of life.   Long-term success often depends on sustained engagement with therapy and supportive interventions. Regular follow-up appointments allow providers to track progress carefully and ensure that care remains aligned with evolving needs.

 

Determining Candidacy for SPRAVATO® (esketamine)

SPRAVATO® (esketamine) is generally appropriate for adults diagnosed with major depressive disorder who have not responded adequately to at least two antidepressant medications. It may also be considered in certain cases involving significant depressive symptoms accompanied by acute suicidal ideation, depending on clinical evaluation.   Not all patients are candidates. Individuals with uncontrolled hypertension, certain cardiovascular conditions, specific substance use histories, or particular psychiatric comorbidities may require alternative approaches. A thorough screening process helps identify potential risks and ensure safety.   Emotional readiness is also important. Because SPRAVATO® (esketamine) requires regular in-office visits at either the Newport Beach or San Juan Capistrano location, patients should be prepared to commit to a structured schedule. Those who value attentive medical oversight and collaborative care often find reassurance in this format.   Ultimately, candidacy is determined through individualized assessment rather than a one-size-fits-all model.

 

Taking the Next Step Toward Meaningful Relief

Persistent depression can feel isolating, but expanded treatment options offer renewed possibilities. SPRAVATO® (esketamine) for treatment-resistant depression in Orange County provides a scientifically grounded approach for patients who have not found relief through traditional therapies.   If you are considering advanced depression treatment, scheduling a consultation at Resiliency Mind+Body Medicine in Orange County, CA, allows for a comprehensive evaluation and thoughtful discussion of your options. A personalized treatment plan may help you move toward greater stability, resilience, and sustained emotional well-being.